FDA Approves Seqirus' Fluad, First U.S. Adjuvanted Flu Vaccine

Tuesday, December 1, 2015

Source: Fierce Vaccines

The U.S. has its first publicly available adjuvanted seasonal flu vaccine in Fluad, formerly a Novartis ($NVS) shot that is now owned by CSL's Seqirus unit.

The vaccine, first approved in Italy in 1997 and now licensed in 38 countries, received FDA accelerated approval for people aged 65 and older last week. With the decision, CSL's flu vaccines unit Seqirus has its first regulatory blessing since its formation in October.

View All News »